- Home
- ORIC vs KROS Comparison
ORIC vs KROS Comparison
Compare ORIC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- KROS
- Stock Information
- Founded
- ORIC 2014
- KROS 2015
- Country
- ORIC United States
- KROS United States
- Employees
- ORIC N/A
- KROS N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- KROS Health Care
- Exchange
- ORIC Nasdaq
- KROS Nasdaq
- Market Cap
- ORIC 1.1B
- KROS 565.0M
- IPO Year
- ORIC 2020
- KROS 2020
- Fundamental
- Price
- ORIC $13.99
- KROS $15.91
- Analyst Decision
- ORIC Strong Buy
- KROS Buy
- Analyst Count
- ORIC 8
- KROS 14
- Target Price
- ORIC $16.57
- KROS $20.56
- AVG Volume (30 Days)
- ORIC 1.7M
- KROS 424.2K
- Earning Date
- ORIC 11-11-2025
- KROS 11-05-2025
- Dividend Yield
- ORIC N/A
- KROS N/A
- EPS Growth
- ORIC N/A
- KROS N/A
- EPS
- ORIC N/A
- KROS 0.47
- Revenue
- ORIC N/A
- KROS $232,844,000.00
- Revenue This Year
- ORIC N/A
- KROS $6,657.47
- Revenue Next Year
- ORIC N/A
- KROS N/A
- P/E Ratio
- ORIC N/A
- KROS $34.14
- Revenue Growth
- ORIC N/A
- KROS 85820.30
- 52 Week Low
- ORIC $3.90
- KROS $9.12
- 52 Week High
- ORIC $14.93
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ORIC 67.45
- KROS 54.08
- Support Level
- ORIC $13.24
- KROS $15.50
- Resistance Level
- ORIC $14.93
- KROS $16.44
- Average True Range (ATR)
- ORIC 0.81
- KROS 0.57
- MACD
- ORIC 0.25
- KROS -0.01
- Stochastic Oscillator
- ORIC 80.50
- KROS 59.87
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.